natgillin/translations-raw huggingface dataset:
Zavrta je tudi agregacija trombocitov, ki jo izzovejo drugi agonisti kot ADP, ker pride do blokade ojačenja trombocitne aktivacije 
Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.
PODATKI V BRAILLOVI PISAVI Klopidogrel Teva Pharma B.V. 75 mg 
INFORMATION IN BRAILLE Clopidogrel Teva Pharma B.V. 75 mg
Pri podganah in pavijanih so poročali tudi o slabem želodčnem prenašanju (gastritis, želodčne erozije in/ali bruhanje), pri uporabi zelo velikih odmerkov. 
At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon.
Filmska obloga laktoza monohidrat hipromeloza (E464) titanov dioksid (E171) makrogol 4000 rdeči železov oksid (E172) rumeni železov oksid (E172) indigotin (E132) 
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Macrogol 4000
podaljšan čas krvavitve, krvavitve v dihalih, krvavitve v očesu, kri v urinu in/ali purpura (rdeče pike na koži, ki nastajajo zaradi krvavitev pod kožo), 
Prolonged bleeding, bleeding inside the head, bleeding in the eye, blood in the urine and/or purpura (red spots on the skin caused by bleeding underneath the skin) Rashes, itching, abnormal touch sensation
tveganja za žilne dogodke in ki niso primerni za zdravljenje z antagonisti vitamina K (VKA) ter imajo majhno tveganje za krvavitev, je klopidogrel v kombinaciji z ASA indiciran za preprečevanje aterotrombotičnih in trombemboličnih dogodkov, vključno z možgansko kapjo. 
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
V primeru potrjenega izoliranega podaljšanja aktiviranega parcialnega tromboplastičnega časa (aPTČ) 
In cases of confirmed isolated activated Partial Thromboplastin Time (aPTT) prolongation with or without bleeding, acquired haemophilia should be considered.
Vendar pa so bolniki, ki so bili vključeni v klinična preskušanja klopidogrela, sočasno prejemali različna zdravila, vključno z diuretiki, blokatorji beta, zaviralci angiotenzinske konvertaze, kalcijevimi antagonisti, sredstvi za zmanjševanje ravni holesterola, koronarnimi vazodilatatorji, antidiabetiki 
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev. 
Your doctor should have prescribed Clopidogrel Teva Pharma B.V. plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
Med ultrahitrimi, dobrimi in srednjimi metabolizatorji niso ugotovili bistvenih razlik v izpostavljenosti aktivnemu presnovku in povprečnem zavrtju agregacije trombocitov (IPA). 
No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultrarapid, extensive and intermediate metabolisers.
odrgnine, hematomi (neobičajne krvavitve pod kožo), krvavitve iz nosu, krvavitve iz želodca ali črevesja, povečane krvavitve na mestu vboda, 
• Bruising, haematoma (unusual bleeding under the skin), nose bleeds, bleeding in the stomach or bowels, increased bleeding at the site of a puncture wound
ustreza polno funkcionalni presnovi, medtem ko alela CYP2C19*2 
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional.
s placebom je bila krvavitev, vendar se pojavljanje krvavitev med skupinama ni značilno razlikovalo. 
Bleeding was the most frequently reported adverse reaction in both clopidogrel and placebo groups; however, there was no significant difference in the bleeding rate between groups.
Če ste pozabili vzeti zdravilo Klopidogrel Teva Pharma B.V. 
If you forget to take Clopidogrel Teva Pharma B.V.
Bolniki so dobivali klopidogrel (300 mg udarni odmerek, nato pa 75 mg na dan, n=1.752) ali placebo (n=1.739), oboje v kombinaciji z acetilsalicilno kislino (150 do 325 mg kot udarni odmerek, nato 75 do 162 mg na dan) 
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Ne jemljite zdravila Klopidogrel Teva Pharma B.V. 
Do not take Clopidogrel Teva Pharma B.V.
Tel: +44 (0) 1977 628500 
United Kingdom Teva UK Limited Tel: +44 (0) 1977 628500
Ušesne bolezni vrtoglavica 
Hepatic impairment
Druga zdravila in zdravilo Kopidogrel Teva Pharma B.V. 
Other medicines and Clopidogrel Teva Pharma B.V.
Nedavna ishemična kap 
Recent ischaemic stroke
Povprečna največja koncentracija nespremenjenega klopidogrela v plazmi (približno 2,2-2,5 ng/ml po enem 75-mg peroralnem odmerku) 
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing.
Krvavitev 
Bleeding
skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve nizek 
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups.
Odmerek 0,2 mg/kg je dosegel povprečno 49,3 % zavrtje (agregacija trombocitov povzročena 
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking clopidogrel 75 mg/day.
imate neredno bitje srca, motnjo, imenovano "atrijska fibrilacija", in ne morete prejemati zdravil, imenovanih "peroralni antikoagulanti" (antagonisti vitamina K), ki preprečujejo nastajanje novih krvnih strdkov in preprečujejo rast obstoječih krvnih strdkov. Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Klopidogrel Teva Pharma B.V. 
• You have an irregular heartbeat, a condition called ‘atrial fibrillation', and you cannot take medicines known as ‘oral anticoagulants' (vitamin K antagonists) which prevent new clots from forming and prevent existing clots from growing.
Žilne bolezni hematom resne krvavitve, krvavitev operacijske rane, vaskulitis, hipotenzija 
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension
Kaj vsebuje navodilo 
What is in this leaflet
spremembe vedenja, glavoboli, koma, motnje vida, napadi (krči), odpovedovanje ledvic, povišana telesna temperatura, huda utrujenost, šibkost ali krvavitve iz želodca, črevesja ali kože (vključno z manjšimi rdečimi madeži ali večjimi odrgninami). 
• Altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas).
Bolezni krvi in limfatičnega sistema nevtropenija, vključno 
Blood and the lymphatic system disorders
so nekateri polimorfni ali podvrženi zavrtju z drugimi zdravili, se ustrezno zavrtje trombocitov ne pojavi pri vseh bolnikih. 
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other medicinal products, not all patients will have adequate platelet inhibition.
so pri bolnikih z ledvično okvaro omejene. 
Therapeutic experience with clopidogrel is limited in patients with renal impairment.
Neželene reakcije, ki so se pojavile v kliničnih študijah ali o katerih 
Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented in the table below.
Pri sočasni uporabi 80 mg pantoprazola enkrat dnevno, so se zmanjšale plazemske koncentracije aktivnega presnovka za 20 % (začetni odmerek) in 14 % (vzdrževalni odmerek), z zmanjšanjem zavrtja agregacije trombocitov za 15 % in 11 %. Ti rezultati kažejo, da se klopidogrel lahko uporablja skupaj s pantoprazolom. 
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily.
statistično značilne razlike v deležih krvavitev s smrtnim izidom (1,1 % klopidogrel + acetilsalicilna kislina, 0,7 % placebo + acetilsalicilna kislina) 
There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.
Zato je potrebno pri tej skupini bolnikov klopidogrel uporabljati previdno (glejte poglavje 4.2). 
Clopidogrel should therefore be used with caution in this population (see section 4.2).
POGOJI ALI OMEJITVE V ZVEZI 
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
ŠTEVILOM ENOT 
BATCH NUMBER
se je pojavila pri 296 (7,8 %) bolnikih, ki so prejemali klopidogrel + acetilsalicilno kislino, in pri 408 (10,8 %) bolnikih, ki so prejemali placebo + acetilsalicilno kislino (relativno zmanjšanje 
Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001).
Zdravilna učinkovina je klopidogrel. 
The active substance is clopidogrel.
in omeprazol uporabljena skupaj istočasno ali v presledku 12 ur, se je izpostavljenost aktivnemu presnovku klopidogrela zmanjšala za 45 % (začetni odmerek) oz. 
Omeprazole 80 mg once daily administered either at the same time as clopidogrel or with 12 hours between the administrations of the two drugs decreased the exposure of the active metabolite by 45% (loading dose) and 40% (maintenance dose).
s placebom, kar predstavlja absolutno zmanjšanje za 6,7 % in 36 % zmanjšanje verjetnosti v prid klopidogrela (95 % IZ od 24 % do 47 %; p<0,001) v glavnem zaradi zmanjšanja pojavnosti zaradi infarkta zamašenih arterij. 
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries.
motnje okušanja, 
Taste disturbances
s preskusi agregacije trombocitov ex vivo, se razlikuje glede na genotip CYP2C19. 
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
- če je zamuda več kot 12 ur: bolnik naj naslednji odmerek vzame ob pravem času; 
- For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, nevedno v poglavju 6.1. 
• Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section
Pri sočasni uporabi klopidogrela z atenololom, nifedipinom, ali z obema - atenololom in nifedipinom - niso opazili nobenih klinično pomembnih farmakodinamičnih interakcij. 
No clinically significant pharmacodynamic interactions were observed when clopidogrel was co administered with atenolol, nifedipine, or both atenolol and nifedipine.
in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT =18,2 %; IZ: 6,5 %, 28,3 %). 
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%).
Zdravilo Klopidogrel Teva Pharma B.V. vsebuje laktozo 
Clopidogrel Teva Pharma B.V. contains lactose
Plodnost Šudije na živalih niso pokazale, da bi klopidogrel vplival na plodnost. 
Fertility Clopidogrel was not shown to alter fertility in animal studies.
HDPE steklenička po 30 tablet: 
30 tablets HDPE bottle:
Za dodatne informacije glejte navodilo za uporabo. 
See leaflet for further information
Aktivni presnovek klopidogrela selektivno zavira vezavo adenozin-difosfata (ADP) na njegov trombocitni receptor P2Y12 
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v 
Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide).
se statistično ni razlikoval od acetilsalicilne kisline (zmanjšanje RT=4,0 %; IZ: -22,5 do 11,7 [p=0,639]). 
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR=-4.0%; CI: -22.5 to 11.7 [p=0.639]).
Zdravilo Klopidogrel Teva Pharma B.V. je na voljo v perforiranih pretisnih omotih iz aluminija, ki se odlepijo, in sicer po 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 tablet; ter perforiranih pretisnih omotih iz aluminija, in sicer po 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 
Clopidogrel Teva Pharma B.V. is supplied in peelable perforated blisters of aluminium/ aluminium containing 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 tablet; perforated blisters of aluminium/ aluminium containing 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 tablet or HDPE bottles with polypropylene closures or child resistant polypropylene closures and silica gel desiccant containing 30 or 100 tablets.
Klopidogrel Teva Pharma B.V. 75 mg filmsko obložene tablete klopidogrel 
Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel
Klopidogrel 
Breast-feeding
Z ZDRAVILOM Teva Pharma B.V. 
Teva Pharma B.V.,
Zdravilo Klopidogrel Teva Pharma B.V. vsebuje laktozo. 
Clopidogrel Teva Pharma B.V. contains lactose.
IME IMETNIKA DOVOLJENJA 
MARKETING AUTHORISATION HOLDER
Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland 
Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland Tél/Tel: +49 731 402 02
Zdravilo Klopidogrel Teva Pharma B.V. vam je bilo predpisano v naslednjih primerih: 
You have been prescribed Clopidogrel Teva Pharma B.V. because:
Navodila za odstranjevanje tablet 
Push the tablet out
gre večina alelov z zmanjšanim delovanjem pri Kavkazijcih(85%) in pri Azijcih (99 %), ki so slabi metabolizatorji. 
The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers.
HDPE stekleničke po 30 tablet: 
30 tablets HDPE bottles:
Občasni neželeni učinki (pojavijo se lahko pri največ 1 od 100 bolnikov): 
Uncommon side effects (may affect up to 1 in 100 people):
so preprečili z zmanjšanjem relativnega tveganja: 22 % v 0. - 1. mesecu (IZ: 8,6, 33,4), 32 % v 1. 
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
s placebom + acetilsalicilno kislino (6,7 % v primerjavi s 4,3 %). 
In ACTIVE-A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%).
Ko jemljete zdravilo Klopidogrel Teva Pharma B.V.: 
While you are taking Clopidogrel Teva Pharma B.V.:
Bolezni kože in podkožja bulozni dermatitis (toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), angioedem, z zdravili povzročen 
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus
Klopidogrel se najprej presnovi v 2-oksoklopidogrel, ki je vmesen presnovek. 
Clopidogrel is first metabolised to a 2-oxo-clopidogrel intermediate metabolite.
- Akutni miokardni infarkt z elevacijo ST spojnice: klopidogrel je potrebno dajati v enkratnem dnevnem odmerku 75 mg, zdravljenje pa je potrebno začeti 
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics.
HDPE stekleničke po 100 tablet: 
100 tablets HDPE bottles:
Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid). 
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA) - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
spomnite po več kot 12 urah, izpustite pozabljeni odmerek in naslednji odmerek vzemite ob običajnem času. 
If you forget to take a dose of Clopidogrel Teva Pharma B.V., but don't remember within 12 hours of the missed dose, skip the missed dose and take the next tablet at the usual time.
s klopidogrelom 
Film-coating
IME ZDRAVILA IN POT(I) UPORABE Klopidogrel Teva Pharma B.V. 75 mg filmsko obložene tablete klopidogrel peroralna uporaba 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel oral use
in približno 46 % z blatom v 120 urnem intervalu po odmerjanju. Po enem peroralnem odmerku 75 mg je razpolovni čas klopidogrela približno 6 ur. Razpolovni čas izločanja glavnega (neaktivnega) krožečega metabolita je bil 8 ur po enkratnem in večkratnem dajanju. 
The elimination half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration.
Po uporabi klopidogrela je bila opisana pridobljena hemofilija. 
Acquired haemophilia has been reported following use of clopidogrel.
Pridobljena hemofilija 
Acquired haemophilia
tiklopidin, druga antiagregacijska zdravila, 
• Ticlopidine, other antiplatelet agent.
Kako jemati zdravilo Klopidogrel Teva Pharma B.V. 
How to take Clopidogrel Teva Pharma B.V.
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): 
Rare side effects (may affect up to 1 in 1000 people):
cimetidina, ki je CYP2C19 inhibitor) ali antacidi, ovirajo antitrombocitno delovanje klopidogrela. 
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel.
ZUNANJA 
Excipients
Dojenje 
Haematoma
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): 
Very rare side effects (may affect up to 1 in 10,000 people):
Če med zdravljenjem z zdravilom Klopidogrel Teva Pharma B.V. zanosite, se takoj posvetujte 
If you become pregnant while taking Clopidogrel Teva Pharma B.V., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
IME ZDRAVILA Klopidogrel Teva Pharma B.V. 75 mg filmsko obložene tablete 
NAME OF THE MEDICINAL PRODUCT Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets
ETIKETA STEKLENIČKE (30 in 100 filmsko obloženih tablet) 
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING BOTTLE LABEL (30 or 100 film-coated tablets)
spomnite do 12 ur od vašega običajnega časa jemanja, takoj vzemite tableto. 
If you forget to take a dose of Clopidogrel Teva Pharma B.V., but remember within 12 hours of the missed dose, take your tablet straight away and then take your next tablet at the usual time.
Študija je ocenila farmakokinetiko in antiagregacijski odziv po uporabi odmerka 300 mg in potem 75 mg/dan ter 600 mg in potem 150 mg/dan, vsako od obeh shem skupaj 5 dni (stanje dinamičnega ravnovesja). 
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
trombocitov podobno kot pri zdravih preiskovancih. Tudi povprečno podaljšanje časa krvavitve je bilo v obeh skupinah podobno. 
The mean bleeding time prolongation was also similar in the two groups.
zmanjšanje števila belih krvnih celic, zaradi česar je tveganje za okužbo večje (nevtropenija), 
Reduced levels of certain white blood cells which increases the risk of infection (neutropenia) Vertigo (dizziness accompanied by a whirling sensation) Bleeding inside the abdomen
ter z/brez uporabe trombolitikov. Pri bolnikih, ki so starejši od 75 let, je treba zdravljenje 
For patients over 75 years of age clopidogrel should be initiated without a loading dose.
ŠKATLICA za stekleničke (30 ali 100 filmsko obloženih tablet) 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON of bottles (30 or 100 film-coated tablets)
sistemske hipertenzije; predhodno možgansko kap, tranzitorno ishemično atako (TIA) ali sistemski embolus (ne v osrednjem živčevju); disfunkcijo levega prekata z iztisnim deležem levega prekata (LVEF) < 45 %; ali dokumentirano bolezen perifernih žil. Povprečna ocena CHADS2 je bila 2,0 (razpon: od 0 do 6). 
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age ≥75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease.
Če dojite ali nameravate dojiti, se pred jemanjem 
If you are breastfeeding or planning to breastfeed, talk to your doctor before taking this medicine.
Zlasti post-hoc analiza podatkov 2172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi 
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
s kombinacijo klopidrogela in ASA, ki bi bilo daljše od štirih tednov, v tem okviru 
The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1).
V študiji CURE je 823 (6,6 %) bolnikov sočasno prejemalo 
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
- Perforirani pretisni omoti vsebujejo 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 filmsko obložena tableta. 
- Perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet.
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom. 
- If you have any side effects, including any side effects not listed in this leaflet, talk your doctor or pharmacist.
Otroci in mladostniki Ne dajajte 
Posology: • Adults and older people